OTC Markets OTCPK - Delayed Quote USD

Pharmagreen Biotech Inc. (PHBI)

Compare
0.0042 +0.0002 (+5.00%)
At close: 3:52 PM EDT
Loading Chart for PHBI
DELL
  • Previous Close 0.0040
  • Open 0.0043
  • Bid 0.0038 x --
  • Ask 0.0042 x --
  • Day's Range 0.0037 - 0.0043
  • 52 Week Range 0.0003 - 0.0047
  • Volume 1,165,167
  • Avg. Volume 5,584,156
  • Market Cap (intraday) 2.787M
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date Sep 5, 2024 - Sep 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. Its primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. The company also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services. It sells its products through online stores, such as Amazon and Shopify. Pharmagreen Biotech Inc. is headquartered in Coquitlam, Canada.

www.pharmagreen.ca

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: PHBI

View More

Research Reports: PHBI

View More

Performance Overview: PHBI

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHBI
600.00%
S&P 500
22.49%

1-Year Return

PHBI
740.00%
S&P 500
35.00%

3-Year Return

PHBI
83.78%
S&P 500
30.66%

5-Year Return

PHBI
99.80%
S&P 500
95.03%

Compare To: PHBI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHBI

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    2.65M

  • Enterprise Value

    3.05M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.19k

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.95k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -151.36%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    4.35k

  • Net Income Avi to Common (ttm)

    -403.84k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    246

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    4.36k

Research Analysis: PHBI

View More

Company Insights: PHBI

People Also Watch